Management of hypertension.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D001581:Benzothiadiazines; D003000:Clonidine / Q000627:therapeutic use; D004232:Diuretics; D004976:Ethacrynic Acid / Q000627:therapeutic use; D005665:Furosemide / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000178:diet therapy / Q000188:drug therapy / Q000628:therapy*; D008750:Methyldopa / Q000627:therapeutic use; D010347:Patient Care Planning; D010349:Patient Compliance; D011433:Propranolol / Q000627:therapeutic use; D046948:Secologanin Tryptamine Alkaloids / Q000627:therapeutic use; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use; D013148:Spironolactone / Q000627:therapeutic use; D014223:Triamterene / Q000627:therapeutic use; D014294:Trimethaphan / Q000627:therapeutic use; D014655:Vascular Resistance / Q000187:drug effects; D014665:Vasodilator Agents / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D001581:Benzothiadiazines; D004232:Diuretics; D046948:Secologanin Tryptamine Alkaloids; D049993:Sodium Chloride Symporter Inhibitors; D014665:Vasodilator Agents; D013148:Spironolactone; D008750:Methyldopa; D014294:Trimethaphan; D005665:Furosemide; D011433:Propranolol; D004976:Ethacrynic Acid; D003000:Clonidine; D014223:Triamterene